To date, CIDRZ TB research has focused on combating the Zambian and global TB burden through identifying evidence-based methods to scale up intensified TB case-finding; improving treatment for TB infected and TB/HIV infected patients; and testing TB vaccines and improved diagnostic methods for use in resource limited settings.
Key studies that the CIDRZ TB Department has conducted are:
- The Centers for Disease Control and Prevention (CDC) Cohort study to identify the burden of TB in HIV-infected patients and enhance systems for TB screening and linking to care
- The US National Institutes of Health Adult AIDS Clinical Trials Group research network identifying improved strategies to manage TB/HIV co-infected patients
- The WHO Stop TB Partnership TB REACH implementation of TB/HIV screening programme for over 7600 inmates in 6 prisons
Ongoing TB implementation science research includes:
- The CDC-funded Op-X study introducing Xpert MTB/RIF in a rural setting
- The CDC-funded 3 ‘I’s program of intensified case finding using Xpert MTB/RIF, improved infection control and provision of Isoniazid preventive therapy
- The AERAS-funded TB vaccine trial using GlaxoSmithKline Biologicals’ candidate recombinant Mycobacterium tuberculosis vaccine, M72/AS01E (GSK 692342)
The TB Department has also been active in diagnostic evaluations; field-testing use of the LED fluorescence microscopes and piloting use of lipoarabinomannan (LAM) in urine to identify TB infection. In addition, we are involved with a public-private collaboration to develop a computer-assisted digital x-ray interpretation technology for TB diagnosis for use in resource-limited settings with shortage of trained health care workers.